Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia

Anemia

Volumn 2013, Issue , 2013, Pages

  Hussain, Iftikhar ^a   Bhoyroo, Jessica ^a   Butcher, Angelia ^b   Koch, Todd A ^b   He, Andy ^b   Bregman, David B ^b,c  

^a Vital Prospects Clinical Research Institute PC   (United States)

^b Luitpold Pharmaceuticals Inc   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884235116     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2013/169107     Document Type: Article

References (32)

1. Lyseng-Williamson K. A., Keating G. M., Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009 69 6 739 756 2-s2.0-65949107825 10.2165/00003495-200969060-00007
2. Clark S. F., Iron deficiency anemia: diagnosis and management. Current Opinion in Gastroenterology 2009 25 2 122 128 2-s2.0-64349113606 10.1097/MOG.0b013e32831ef1cd
3. Anonyme, Ferric carboxymaltose: a breakthrough treatment for iron deficiency anaemia. European Journal of Hospital Pharmacy Practice 2009 15 62 65
4. Van Wyck D. B., Martens M. G., Seid M. H., Baker J. B., Mangione A., Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstetrics and Gynecology 2007 110 2 I 267 278 2-s2.0-34548462994 10.1097/01.AOG.0000275286.03283.18
5. Goodnough L. T., Van Wyck D. B., Mangione A., Morrison J., Hadley P. E., Jehle J. A., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009 49 12 2719 2728 2-s2.0-71849101678 10.1111/j.1537-2995.2009. 02327.x
6. Gasche C., Lomer M. C. E., Cavill I., Weiss G., Iron, anaemia, and inflammatory bowel diseases. Gut 2004 53 8 1190 1197 2-s2.0-3242698640 10.1136/gut.2003.035758
7. Clark S. F., Iron deficiency anemia. Nutrition in Clinical Practice 2008 23 2 128 141 2-s2.0-41949113085 10.1177/0884533608314536
8. Danielson B. G., Geisser P., Schneider W., Iron Therapy with Special Emphasis on Intravenous Administration 1996 Vifor (International) Inc.
9. Silverstein S. B., Gilreath J. A., Rodgers G. M., Intravenous iron therapy: a summary of treatment options and review of guidelines. Journal of Pharmacy Practice 2008 21 6 431 443 2-s2.0-57249114491 10.1177/0897190008318916
10. Fishbane S., Ungureanu V.-D., Maesaka J. K., Kaupke C. J., Lim V., Wish J., The safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Diseases 1996 28 4 529 534 2-s2.0-0029795844
11. Van Wyck D. B., Anderson J., Johnson K., Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrology Dialysis Transplantation 2004 19 3 561 565 2-s2.0-1342306211 10.1093/ndt/gfg579
12. Santosh S., Podaralla P., Miller B., Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol. NDT Plus 2010 3 4 341 342 2-s2.0-77956028834 10.1093/ndtplus/sfq084
13. Kulnigg S., Stoinov S., Simanenkov V., Dudar L. V., Karnafel W., Garcia L. C., Sambuelli A. M., D'Haens G., Gasche C., A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology 2008 103 5 1182 1192 2-s2.0-43549093318 10.1111/j.1572-0241. 2007.01744.x
14. Auerbach M., Ballard H., Clinical use of intravenous iron: administration, efficacy, and safety. Hematology/the Education Program of the American Society of Hematology 2010 2010 338 347 2-s2.0-79955045302
15. Tagboto S., Cropper L., Turner J., Pugh-Clarke K., The efficicacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Journal of Renal Care 2009 35 1 18 22 2-s2.0-61849169432 10.1111/j.1755-6686.2009.00075.x
16. Ganzoni A. M., Total infusion of ferri-carbohydrate complexes. Blut 1972 25 349 351
17. Wilson P. W. F., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B., Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 18 1837 1847 2-s2.0-0032510639
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS March 2003, http://ctep.cancer.gov/
19. Geisser P., Banké-Bochita J., Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittel-Forschung 2010 60 6 a 362 372 2-s2.0-77956857469
20. Bailey G., Strub R. L., Klein R. C., Salvaggio J., Dextran-induced anaphylaxis. Journal of the American Medical Association 1967 200 10 889 891 2-s2.0-0014193389 10.1001/jama.200.10.889
21. Fishbane S., Safety in iron management. American Journal of Kidney Diseases 2003 41 6 S18 S26 2-s2.0-0038777439
22. Danielson B. G., Structure, chemistry, and pharmacokinetics of intravenous iron agents. Journal of the American Society of Nephrology 2004 15 2 S93 S98 2-s2.0-9644257204 10.1097/01.ASN.0000143814.49713.C5
23. Lawrence R., Helenek M., Development and comparison of iron dextran products. PDA Journal of Pharmaceutical Science and Technology 1998 52 5 190 197 2-s2.0-0031738096
24. Fletes R., Lazarus J. M., Gage J., Chertow G. M., Suspected iron dextran-related adverse drug events in hemodialysis patients. American Journal of Kidney Diseases 2001 37 4 743 749 2-s2.0-0035057037
25. McCarthy J. T., Regnier C. E., Loebertmann C. L., Bergstralh E. J., Adverse events in chronic hemodialysis patients receiving intravenous iron dextran-a comparison of two products. American Journal of Nephrology 2000 20 6 455 462 2-s2.0-0034525862 10.1159/000046199
26. Walters B. A. J., Van Wyck D. B., Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrology Dialysis Transplantation 2005 20 7 1438 1442 2-s2.0-26044434869 10.1093/ndt/gfh811
27. Barish C. F., Koch T., Butcher A., Morris D., Bregman D. B., Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency Anemia: two randomized, controlled trials. Anemia 2012 2012 12 10.1155/2012/172104 172104
28. Charytan C., Bernardo M. V., Koch T., Butcher A., Morris D., Bregman D. B., Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrology Dialysis Transplantation 2013 28 953 964 10.1093/ndt/gfs528
29. Wolf M., Koch T. A., Bregman D. B., Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of Bone and Mineral Research 2013 28 8 1793 1803 10.1002/jbmr.1923
30. Seid M. H., Derman R. J., Baker J. B., Banach W., Goldberg C., Rogers R., Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. American Journal of Obstetrics and Gynecology 2008 199 4 435.e1 435.e7 2-s2.0-52949101033 10.1016/j.ajog.2008. 07.046
31. Breymann C., Gliga F., Bejenariu C., Strizhova N., Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. International Journal of Gynecology and Obstetrics 2008 101 1 67 73 2-s2.0-40649100958 10.1016/j.ijgo.2007.10.009
32. Anker S. D., Colet J. C., Filippatos G., Willenheimer R., Dickstein K., Drexler H., Lüscher T. F., Bart B., Banasiak W., Niegowska J., Kirwan B.-A., Mori C., Von Eisenhart Rothe B. E., Pocock S. J., Poole-Wilson P. A., Ponikowski P., Ferric carboxymaltose in patients with heart failure and iron deficiency. The New England Journal of Medicine 2009 361 25 2436 2448 2-s2.0-72449156527 10.1056/NEJMoa0908355